首页> 外国专利> Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure

Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure

机译:向中枢神经系统输送能引起交感的心血管药物,以对抗心力衰竭和与心力衰竭相关的病理

摘要

A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms and otherwise treat heart failure (HF) and pathologies associated with HF. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with HF (or pathologies associated with HF) and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist, e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine.
机译:由药物输送泵输送到中枢神经系统部位的交感性心血管药物,可减轻症状并以其他方式治疗心力衰竭(HF)和与HF相关的病理。药物输送泵可以是外部或可植入的输液泵(IIP),其与延伸到该部位的药物输液导管相连。患者激活器可以命令输送剂量和/或与传感器耦合的可植入式心脏监护仪(IHM)可以检测与HF相关的生理参数(或与HF相关的病理)并触发剂量输送。 IIP和IHM可以组合为单个可植入医疗设备(IMD),也可以构成通过任何已知通信机制进行通信的独立IMD。交感神经药是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂组成的组中的一种,例如可乐定,对氨基可乐定,胍阿宾斯,利达lid啶,替扎尼定,莫索尼定,甲基多巴,甲苯噻嗪,胍法辛,地托美定,美托咪定和右美托咪定。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号